<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="http://medicalxpress.com/tmpl/default/css/default/feedRSS.xsl"?>
<rss version="2.0" 
	xmlns:media="http://search.yahoo.com/mrss/">
<channel>
<title>Medical Xpress: PHYSorg news tagged with: neuroblastoma cells</title>
<link>http://medicalxpress.com/</link>
<language>en-us</language> 
<description>Medical Xpress internet news portal provides the latest news on Health and Medicine.</description>

 <item>
     <title>Genetic biomarker may help identify neuroblastomas vulnerable to novel class of drugs</title>
   	 <description>An irregularity within many neuroblastoma cells may indicate whether a neuroblastoma tumor, a difficult-to-treat, early childhood cancer, is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors, Dana-Farber/Children's Hospital Cancer Center scientists will report at the annual meeting of the American Association for Cancer Research in Washington, April 6-10.</description>
     <link>http://medicalxpress.com/news/2013-04-genetic-biomarker-neuroblastomas-vulnerable-class.html</link>
	 <category>Cancer</category>
	 <pubDate>Tue, 09 Apr 2013 16:00:09 EST</pubDate>
	 <guid isPermaLink="false">news284735117</guid>
	 
</item>
<item>
     <title>Biomarker may identify neuroblastomas with sensitivity to BET bromodomain inhibitors</title>
   	 <description>Neuroblastoma, the most common malignant tumor of early childhood, is frequently associated with the presence of MYCN amplification, a genetic biomarker associated with poor prognosis. Researchers have determined that tumors containing MYCN amplification are sensitive to a new class of drugs, BET bromodomain inhibitors.</description>
     <link>http://medicalxpress.com/news/2013-02-biomarker-neuroblastomas-sensitivity-bromodomain-inhibitors.html</link>
	 <category>Cancer</category>
	 <pubDate>Thu, 21 Feb 2013 10:32:14 EST</pubDate>
	 <guid isPermaLink="false">news280665121</guid>
	 
</item>
<item>
     <title>Targeting downstream proteins in cancer-causing pathway shows promise in cell, animal model</title>
   	 <description>The cancer-causing form of the gene Myc alters the metabolism of mitochondria, the cell's powerhouse, making it dependent on the amino acid glutamine for survival. In fact, 40 percent of all &quot;hard-to-treat&quot; cancers have a mutation in the Myc gene.</description>
     <link>http://medicalxpress.com/news/2012-11-downstream-proteins-cancer-causing-pathway-cell.html</link>
	 <category>Cancer</category>
	 <pubDate>Tue, 13 Nov 2012 14:54:46 EST</pubDate>
	 <guid isPermaLink="false">news272040879</guid>
	 
</item>
<item>
     <title>Cell death mystery yields new suspect for cancer drug development</title>
   	 <description>A mysterious form of cell death, coded in proteins and enzymes, led to a discovery by UNC researchers uncovering a prime suspect for new cancer drug development.</description>
     <link>http://medicalxpress.com/news/2012-09-cell-death-mystery-yields-cancer.html</link>
	 <category>Cancer</category>
	 <pubDate>Thu, 13 Sep 2012 10:26:06 EST</pubDate>
	 <guid isPermaLink="false">news266750756</guid>
	 
</item>
<item>
     <title>Progesterone inhibits growth of neuroblastoma cancer cells</title>
   	 <description>High doses of the hormone progesterone can kill neuroblastoma cells while leaving healthy cells unscathed, scientists at Emory University School of Medicine have found in laboratory research.</description>
     <link>http://medicalxpress.com/news/2011-07-progesterone-inhibits-growth-neuroblastoma-cancer.html</link>
	 <category>Cancer</category>
	 <pubDate>Wed, 13 Jul 2011 12:13:59 EST</pubDate>
	 <guid isPermaLink="false">news229777948</guid>
	 
</item>


</channel>
</rss>
